- Novel, highly selective ROCK2 inhibitor GV300 demonstrated enhanced brain penetration, improved solubility and oral bioavailability.
- GV300 ameliorated clinical scores as well as reduced demyelination, inflammation, and biomarkers of neurodegeneration in preclinical models of multiple sclerosis (MS).
- Mechanistic ex vivo studies indicated that selective ROCK2 inhibition promotes oligodendrocyte-mediated myelination and neurite outgrowth, supporting a differentiated approach to target both inflammation and central nervous system (CNS) repair in MS.
- Data support continued development of GV300 for progressive MS, an area of significant unmet medical need due to a lack of therapies addressing neurodegeneration and myelin repair.
NEW YORK, Nov. 16, 2026 /PRNewswire/ -- Graviton BioScience Corporation, a clinical-stage biotechnology company developing a diverse pipeline of therapeutics including highly selective Rho-associated coiled-coil-containing protein kinase 2 (ROCK2) inhibitors for metabolic, inflammatory, fibrotic, and central nervous system disorders, today announced new preclinical data, presented on November 15, demonstrating the potential of highly selective, blood-brain-barrier penetrant ROCK2 inhibitors to simultaneously reduce neuroinflammation and promote central nervous system repair in multiple sclerosis (MS). The research evaluated the ability of Graviton's novel, blood-brain-barrier penetrant, highly selective ROCK2 inhibitor GV300, designed specifically for the treatment of progressive MS, to target both the inflammatory and neurodegenerative components of the disease.
The findings were presented at the Neuroscience 2026 conference in a presentation entitled, "Selective ROCK2 inhibitors ameliorate murine models of multiple sclerosis and demyelination by harnessing inflammation and restoring homeostasis," by Julien Moretti, Ph.D., Director within Graviton's Translational Medicine group, led by Alexandra Zanin-Zhorov, Ph.D., Senior Vice President at Graviton BioScience. The data suggest that GV300 may address multiple drivers of progressive MS, including chronic neuroinflammation, demyelination, neurodegeneration and impaired remyelination.
Key Findings
- Reduced neuroinflammation and demyelination. In the Experimental Autoimmune Encephalomyelitis (EAE) model, therapeutic oral administration of GV300 reduced clinical disease scores and demyelination, lowered spinal cord inflammation and neurodegeneration-associated biomarkers.
- Remyelination in a non-autoimmune model. In a separate non-autoimmune cuprizone-induced demyelination model, GV300 promoted remyelination, supporting an effect beyond modulation of autoimmune inflammation alone.
- Direct effects on CNS repair pathways. Mechanistic studies showed that selective ROCK2 inhibition enhanced oligodendrocyte-mediated myelination, increased microglial clearance of myelin debris and promoted neurite outgrowth.
- Differentiated development profile. GV300 demonstrated potent and highly selective ROCK2 inhibition, improved solubility and oral bioavailability and measurable brain exposure in preclinical studies.
"These findings suggest that selective ROCK2 inhibition has the potential to address multiple components of MS biology simultaneously," said Julien Moretti, Ph.D. "In our preclinical and ex vivo studies, we observed not only a reduction in disease-associated inflammation, but also direct effects on oligodendrocytes, microglia and neurons that are consistent with remyelination and restoration of CNS homeostasis."
"This combination may be particularly important in progressive MS, where neurodegeneration and the failure of effective repair become increasingly important drivers of the disease, while neuroinflammation becomes less dominant," added Alexandra Zanin-Zhorov, Ph.D.
"Patients with progressive multiple sclerosis continue to have limited treatment options, particularly when disease progression occurs independently of relapses," said Samuel D. Waksal, Ph.D., Founder and Chief Executive Officer of Graviton BioScience. "There remains a major need for therapies that go beyond controlling peripheral inflammation and address the mechanisms underlying demyelination, neuronal injury, and progressive disability. These findings provide compelling preclinical evidence that selective, brain-penetrant ROCK2 inhibition, such as GV300, may offer a differentiated approach by going beyond controlling inflammation, while simultaneously targeting cellular pathways involved in myelin repair and neuronal health."
Presentation Details
Title: Selective ROCK2 inhibitors ameliorate murine models of multiple sclerosis and demyelination by harnessing inflammation and restoring homeostasis
Presenter: Julien Moretti, Ph.D., Graviton BioScience
Conference: Neuroscience 2026
Date and Time: Sunday, November 15, 2026, 8:00 a.m.–12:00 p.m.
Session: Translational Studies and Therapeutic Strategies in Multiple Sclerosis
Location: Walter E. Washington Convention Center, Washington, D.C.
About GV300 and Progressive Multiple Sclerosis
Progressive multiple sclerosis is characterized by accumulating neurological disability associated with neuroinflammation, demyelination, neuronal injury and inadequate repair within the central nervous system. Although available therapies can reduce inflammatory disease activity, treatment options remain limited for patients whose disability progresses independently of relapses.
GV300 is Graviton's highly selective, orally available and brain-penetrant ROCK2 inhibitor developed for progressive MS. ROCK2 regulates pro-inflammatory immune signaling as well as cellular pathways involved in neurological function and repair. In preclinical studies, GV300 demonstrated activity across disease severity, inflammation, demyelination, neurodegeneration-associated biomarkers, remyelination and neurite outgrowth.
About Graviton BioScience
Graviton BioScience Corporation is a clinical-stage drug discovery and development company dedicated to engineering and developing best-in-class therapeutics for metabolic, central nervous system, inflammatory, fibrotic and other diseases. Graviton has developed a portfolio of selective ROCK2 inhibitors, among other innovative and novel therapies, for patients with fibrotic, autoimmune, and CNS diseases.
Leading the Company is Samuel D. Waksal, Ph.D., the founder and former Chairman and Chief Executive Officer of Kadmon Pharmaceuticals, which was acquired by Sanofi. Dr. Waksal is also the founder and former Chief Executive Officer of ImClone Systems, which was acquired by Eli Lilly, and a founder of MeiraGTx.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the potential therapeutic benefits of GV300 and selective ROCK2 inhibition, the potential applicability of preclinical findings to multiple sclerosis, including progressive forms of MS, and Graviton BioScience's research and development plans. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. The findings described herein are preclinical, and results observed in preclinical models may not be predictive of results in humans. Forward-looking statements speak only as of the date of this press release, and Graviton BioScience undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Media Contact
Graviton BioScience Corporation
Melanie Glickman
[email protected]
1 (332) 318-2019
SOURCE Graviton BioScience Corporation

Share this article